Roche, Oryzon Form Epigenetics Pact | Chemical & Engineering News
Volume 92 Issue 15 | p. 15 | Concentrates
Issue Date: April 14, 2014

Roche, Oryzon Form Epigenetics Pact

Department: Business
Keywords: pharmaceuticals, biotech, epigenetics, LSD1

Roche will pay Oryzon Genomics up to $21 million in up-front and near-term payments as part of a pact to develop drugs that block lysine-specific demethylase-1 (LSD1), an epigenetic target that regulates gene expression. Under the deal, Roche will take the reins in further developing the Spanish firm’s lead molecule, ORY-1001, which is in Phase I/IIa studies as a treatment for acute myeloid leukemia. Roche also gains the rights to two patent families related to LSD1. The companies will work together to better understand how LSD1 inhibitors can be used to treat cancer.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment